Life Sciences

AstraZeneca to invest $360 million in advanced manufacturing facility in Ireland

By In partnership with

AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland which will allow for late-stage development and early commercial supply through the application of state-of-the-art process technology and digital innovation.

The $360 million planned investment at the Alexion Campus in College Park, Dublin is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs. The project was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland.

The investment programme is expected to significantly reduce commercialization lead times and costs, and introduce more sustainable manufacturing processes, contributing to the AstraZeneca’s Ambition Zero Carbon programme. The company said the industry-leading, future-proof design of the plant would permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.